以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 不久前，国家卫生健康委员会主任雷海潮在新闻发布会上宣布，将启动为期三年的"体重管理年"专项行动，旨在全面推广健康的生活方式。 雷主任介绍，这项行动由国家卫生健康委联合16个部门共同发起，早在去年就已正式实施。其核心目标是引导全民关注体重管理，养成科学饮 食和积极锻炼的健康习惯，让健康生活成为社会新风尚。 这一消息一经发布，立刻引发热议，登上各大热搜榜。网友们纷纷表示："连国家都开始督促减肥了，这次必须认真对待！""减肥，真的是刚需 啊！" 其实，我们身边关于"变胖"的吐槽几乎每天都在发生，这并非无病呻吟。因为，事实就是——中国人正在变得越来越胖！ 在医学领域，"胖"有着明确的衡量标准。世界卫生组织将身体质量指数（BMI）18.5-25视为正常，25-30为超重，超过30则为肥胖。而我国标 准略有不同，BMI在18-24为正常，24-28为超重，超过28则被定义为肥胖。 也就是说，日常所说的"胖"，其实对应的就是医学上的超重和肥胖。 那么中国目前的状况如 ...

Core Insights - Eli Lilly's market capitalization reached $1 trillion, making it the first pharmaceutical company to achieve this milestone [2] - Over the past two years, Eli Lilly's market value has significantly outpaced major competitors like Johnson & Johnson and Novo Nordisk [3] Market Comparison - Eli Lilly's market value of approximately 71,116 billion RMB is equivalent to 4.18 times the total market capitalization of all A-share pharmaceutical companies valued over 1 billion RMB [7][9] - This valuation is roughly equal to the combined market capitalizations of 17.63 Heng Rui Medicine, 22.76 BeiGene, 25.37 WuXi AppTec, 46 Bai Li Tian Heng, or 67 Pian Zai Huang [9]

Core Viewpoint - The article discusses the "Three-Year Action Plan for Weight Management" initiated by the National Health Commission of China, aiming to enhance public awareness and skills in weight management, with a target of reducing the annual obesity rate increase by 10% by 2026 [16][18]. Group 1: Metabolic Miracle of Intermittent Fasting - The Alternate Day Fasting (ADF) method employs a cycle of "1 day of feasting + 1 day of light fasting," allowing the body to self-regulate between "abundant" and "scarce" periods [3]. - Scientific research indicates a dual weight loss mechanism: - Intelligent calorie control with a weekly caloric deficit of up to 37% [3]. - Metabolic switch effect, enhancing fat-burning efficiency by three times after 12 hours of fasting [3]. Group 2: Impressive Weight Loss Results - Clinical data shows an average weight loss of 5.4 kg over 8 weeks, with a waist circumference reduction of 7 cm [5]. - Fat loss constitutes 75% of the total weight loss, significantly surpassing traditional dieting methods [5]. - Muscle retention rate improves by 40%, ensuring that basal metabolic rate does not decline [5]. Group 3: Health Benefits - Cardiovascular health benefits include a 23% reduction in bad cholesterol and a five-year improvement in vascular age [5]. - Cognitive benefits include an 18% increase in memory test scores and enhanced focus [6]. - For women, there is a 67% relief from premenstrual syndrome and more stable emotions [6]. Group 4: Target Audience - The program is particularly suitable for individuals with a BMI over 24, postpartum mothers, and middle-aged individuals with elevated blood sugar levels [11]. Group 5: National Strategy for Weight Management - The "Weight Management Year" initiative is part of a broader national strategy to promote healthy lifestyles and improve public health by 2030 [18]. - The goal is to establish a supportive environment for weight management and to significantly enhance public awareness and skills in this area [18].

Core Insights - The article discusses the effectiveness of Tirzepatide, a dual agonist of GIP and GLP-1 receptors, in weight loss and its clinical results compared to surgical interventions [4]. Group 1: Clinical Research and Results - Tirzepatide has shown significant weight loss results in the SURMOUNT-1 study, where participants lost an average of 16.1 kg, 22.2 kg, and 23.6 kg for doses of 5 mg, 10 mg, and 15 mg respectively over 72 weeks, compared to a mere 2.4 kg in the placebo group [4]. - The drug is administered once a week and has been proven to reduce food intake and increase energy expenditure, contributing to weight loss [4]. Group 2: Personal Experiences and Testimonials - Notable figures like Duan Yongping reported a weight loss of 15 pounds (approximately 13.6 kg) after using Tirzepatide for two and a half months, with no significant side effects [6]. - Whoopi Goldberg shared her experience of losing a substantial amount of weight, stating that the drug has been very beneficial for her [7]. - Lauren Manzo mentioned losing 30 pounds (approximately 27.2 kg) since starting Tirzepatide, claiming it has been more effective than other weight loss methods, including surgery [11]. - Charles Barkley reported a weight loss of 65 pounds (approximately 58.9 kg) while using Tirzepatide, emphasizing the drug's effectiveness compared to traditional weight loss methods [12][14].

Core Viewpoint - The article emphasizes the hidden dangers of visceral fat, which can lead to significant health risks even in individuals with normal body weight. It highlights the importance of awareness regarding visceral fat and its impact on metabolic health and disease risk. Group 1: Visceral Fat as a Health Threat - Visceral fat is the fat that surrounds internal organs such as the liver, pancreas, and intestines, and it is not visible like subcutaneous fat. This type of fat can lead to metabolic disorders and inflammation, posing serious health risks [6][7]. - The World Health Organization (WHO) suggests that a waist circumference of ≥90 cm for men and ≥85 cm for women significantly increases the risk of visceral fat accumulation [7]. - Research published in The Lancet indicates that a 10% increase in visceral fat raises the risk of cardiovascular diseases by 13% and doubles the risk of diabetes [7]. Group 2: Causes of Excess Visceral Fat - High-sugar and high-fat diets are primary contributors to excess visceral fat. Consuming refined carbohydrates and trans fats leads to increased triglyceride synthesis in the liver, resulting in fat accumulation around internal organs. A study from Harvard University found that drinking one sugary beverage daily can increase visceral fat by 15% annually [9]. - Sedentary behavior and lack of exercise significantly contribute to visceral fat accumulation. Data from the Journal of Sports Medicine shows that sitting for two consecutive hours can reduce the activity of fat-decomposing enzymes by 90% [10]. - Chronic stress and lack of sleep also play a role in visceral fat accumulation. High levels of cortisol, the stress hormone, promote fat storage in the abdominal area. Individuals who sleep less than five hours per night accumulate visceral fat 30% faster than those who get adequate sleep [11].

Core Viewpoint - The article highlights the successful results of the phase III clinical trial (GLORY-2) for the drug IBI362 (Masitide) developed by Innovent Biologics, indicating its effectiveness in weight management for adults with moderate to severe obesity in China [4][6]. Group 1: Clinical Trial Results - The GLORY-2 study included 462 adult participants with a baseline average weight of approximately 94.0 kg and an average BMI of about 34.3 kg/m², with 16% having type 2 diabetes [4]. - At week 60, the Masitide 9 mg group experienced an average weight loss of 18.55%, compared to 3.02% in the placebo group, with 44.0% of participants in the Masitide group achieving a weight reduction of 20% or more [6]. - In the subgroup without type 2 diabetes, the Masitide group had an average weight loss of 20.08%, while the placebo group had 2.81%, with 48.7% of participants in the Masitide group achieving a weight reduction of 20% or more [6]. Group 2: Secondary Outcomes - The Masitide 9 mg group showed significant improvements in waist circumference, systolic blood pressure, triglycerides, non-HDL cholesterol, LDL cholesterol, and uric acid levels compared to the placebo group [6]. - MRI-PDFF assessments indicated a 71.9% reduction in liver fat content in the Masitide group among participants with baseline liver fat content ≥10%, while the placebo group saw a 5.1% increase [6]. Group 3: Safety and Tolerability - Masitide 9 mg was well-tolerated, with no new safety signals identified; gastrointestinal adverse events were mostly mild to moderate and transient [6]. - The rate of treatment discontinuation due to adverse events was 2.9% in the Masitide group compared to 0% in the placebo group [6]. Group 4: Drug Mechanism and Development - Masitide is a dual receptor agonist for glucagon and GLP-1, promoting insulin secretion, reducing blood sugar, suppressing appetite, and enhancing energy expenditure and fat metabolism [7]. - Innovent Biologics has initiated or completed multiple phase III studies for Masitide, targeting various populations, including overweight or obese adults and patients with type 2 diabetes [7]. Group 5: Future Indications - The expansion of Masitide's indications is underway, including applications for adolescent obesity, metabolic-associated fatty liver disease (MASH), heart failure with preserved ejection fraction (HFpEF), and head-to-head trials with higher doses and other drugs [8].

Core Viewpoint - The article emphasizes the importance of weight management as part of the "Healthy China 2030" strategy, highlighting that maintaining stable body weight is linked to longevity and overall health [2][28]. Group 1: Research Findings - A study published in the Journal of Gerontology indicates that women who maintain stable body weight are more likely to live to 90 years or older [7][9]. - The research included 54,437 women aged 61 to 81, measuring their weight at baseline, 3 years, and 10 years [8]. - Among the participants, 30,647 women (56%) lived to at least 90 years, with those maintaining stable weight having a 1.2 to 2 times higher chance of longevity compared to those who lost 5% or more of their weight [9]. Group 2: Weight Management Guidelines - The National Health Commission has initiated a three-year action plan for weight management, aiming to enhance public awareness and skills related to weight management by 2026, with a target of reducing the annual obesity rate increase by 10% [28][30]. - The article outlines that a balanced diet and increased physical activity are fundamental for effective weight loss, recommending a gradual weight reduction of 5% to 10% over six months [15][20]. - Specific dietary recommendations include prioritizing whole grains, lean proteins, low-fat dairy, and a variety of fresh fruits and vegetables while controlling total caloric intake [18][20].

Core Insights - Obesity is a significant global public health issue, with a retrospective study revealing a 69.5% incidence of weight regain among patients who underwent sleeve gastrectomy (SG) [6][7] - The study identifies the third year post-surgery as a critical period for weight rebound, with 41.7% of patients experiencing a weight regain of 20% or more of their maximum weight loss, meeting the criteria for weight regain (WR) [6][7][8] Study Overview - The research included 676 patients who underwent SG at Shanghai Jiao Tong University from January 2011 to June 2022, with a median follow-up of three years [6][7] - Factors associated with higher postoperative total weight loss percentage (%TWL) included baseline age, initial BMI, male gender, and absence of hypertension [7] - Among 540 patients with complete follow-up at 1, 3, and 5 years, the rate of weight regain increased from 21.7% at year three to 32.6% at year five [7] Weight Change Patterns - Patients were categorized into three groups based on weight change trajectories: significant weight loss, moderate weight loss, and minimal weight loss [7] - The significant weight loss group had higher baseline BMI, waist circumference, fasting insulin, and insulin resistance index (HOMA-IR) compared to the minimal weight loss group [7] Implications for Future Research - The findings provide a scientific basis for identifying high-risk patients and developing preventive strategies against weight regain after SG [8]

Core Viewpoint - The article discusses the recent developments regarding Eli Lilly's drug Tirzepatide, including its current status in the Chinese market and potential future approvals for additional indications [4][6]. Group 1: Drug Approval Status - On November 17, the National Medical Products Administration (NMPA) of China issued a notification regarding Eli Lilly's Tirzepatide injection, indicating that the application has not yet been approved but can still proceed with further data submission [4]. - The notification includes four application numbers: JXHS2400108, JXHS2400109, JXHS2400110, and JXHS2400111, with a date of issuance on November 14, 2025 [5]. Group 2: Current Indications - Tirzepatide has received approval in China for three indications: for adults with type 2 diabetes who have inadequate blood sugar control, for improving blood sugar control in adults with type 2 diabetes when used with insulin, and for long-term weight management in adults with obesity or overweight [6]. - Additionally, Tirzepatide is approved for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity [6]. Group 3: Speculated Future Indications - Industry insiders speculate that the application may be for the indication of "heart failure with preserved ejection fraction associated with obesity," which is still under registration approval in the United States [5].

Core Viewpoint - The emergence of a new era in disease prevention is highlighted, with GLP-1 receptor agonists (GLP-1s) potentially becoming the first longevity drugs due to their efficacy in treating obesity and type 2 diabetes, as well as their benefits in mitigating age-related chronic diseases [3][4][12]. Group 1: GLP-1s and Longevity - GLP-1s show promise not only in treating obesity and diabetes but also in preventing various age-related diseases, marking a shift towards preventive medicine [4][12]. - Clinical trial data indicates that GLP-1s significantly improve cardiovascular outcomes and reduce all-cause mortality in high-risk populations, with some benefits attributed to anti-inflammatory mechanisms rather than weight loss alone [12][13]. Group 2: Aging Mechanisms and Drug Development - Aging is identified as a major risk factor for late-life diseases, and targeting aging mechanisms could theoretically prevent multiple diseases simultaneously [6][9]. - Research has categorized aging markers into 14 distinct categories, which include genetic, epigenetic, and cellular factors, forming a complex network that is challenging to measure [6][9]. Group 3: Current Status and Future Directions - No anti-aging drugs have been approved yet, although some existing medications may meet the criteria if properly tested. The FDA does not recognize aging as a disease, complicating the regulatory landscape for anti-aging interventions [10][12]. - Ongoing trials are exploring the effects of GLP-1s on diseases beyond obesity and diabetes, including Alzheimer's disease, with promising early results [13][14]. Group 4: Challenges and Considerations - The exploration of GLP-1s for longevity will involve various factors such as disease indicators, formulations, and individual patient responses, with a focus on minimizing side effects [14][16]. - The success of longevity drugs will likely depend on their long-term safety, efficacy, affordability, and the ability to be used in precision medicine approaches [14][16]. Group 5: Broader Research and Development - Pharmaceutical companies are investigating various strategies beyond GLP-1s, including targeting inflammation and other pathways associated with aging, which may have broad implications for healthspan [16][17]. - The TAME trial proposes a more efficient method of assessing multiple chronic diseases as composite outcomes, which could facilitate the approval of anti-aging drugs [17].